doxorubicin-teva
teva pharma b.v. - doksorubicino hidrochloridas - milteliai injekciniam tirpalui - 10 mg; 50 mg - doxorubicin
lidokainas sanitas
pharmaswiss Česká republika s.r.o. - lidokaino hidrochloridas - injekcinis tirpalas - 20 mg/ml - lidocaine
qtrilmet
astrazeneca ab - metforminas hidrochloridas, saxagliptin, dapagliflozin - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - qtrilmet yra nurodyta suaugusiems nuo 18 metų ir vyresni, su 2 tipo cukrinis diabetas:gerinti glycaemic kontrolės, kai metforminas su arba be sulfonilkarbamido dariniai (Šu) ir arba saxagliptin ar dapagliflozin neužtikrina adekvačios glycaemic kontrolės. kai jau gydomi metforminas ir saxagliptin ir dapagliflozin.
maymetsi
krka, d.d., novo mesto - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/850 mg - metformin and sitagliptin
maymetsi
krka, d.d., novo mesto - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/1000 mg - metformin and sitagliptin
asigefort
tad pharma gmbh - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/850 mg - metformin and sitagliptin
asigefort
tad pharma gmbh - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/1000 mg - metformin and sitagliptin
galafold
amicus therapeutics europe limited - migalastat hydrochloride - fabriko liga - migalastat - galafold yra nurodyta ilgalaikiam gydymui suaugusiesiems ir paaugliams nuo 16 metų ir vyresni yra diagnozuota fabry liga (α-galaktozidazės a trūkumas) ir kuriems gali būti taikoma mutacija.
parsabiv
amgen europe b.v. - etelcalcetid hydrochloride - hiperparatiroidizmas, antrinis - anti-parathyroid agents, calcium homeostasis - parsabiv skiriamas antrinio hiperparatiroidizmo (shpt) gydymui suaugusiems pacientams, sergantiems lėtinės inkstų ligos (ckd) hemodializės terapija.
lenalidomide krka d.d. novo mesto (previously lenalidomide krka)
krka, d.d., novo mesto - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - imunosupresantai - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).